At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 500 enrolled
Drug / intervention
Esomeprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Proton Pump Inhibitors Effects on Dyspepsia During Ramadan Fasting
In Brief
A Phase 2 clinical trial evaluating Esomeprazole and Placebo for Dyspepsia. Completed, enrolled 500 participants across 1 site.
Detailed Summary
evaluate the interest of proton pump inhibitors in subjects with or with GI symptoms who intend to observe fasting in Ramadan. The investigators will compare the effectiveness of proton pump inhibitors to prevent or reduce the signs of dyspepsia during Ramadan compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyspepsia
CountriesTunisia
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
Enrollment StartJan 2020
Primary CompletionDec 2020
First PostedMar 2022
Study CompletionDec 2024
TodayJul 2026
First PostedMar 18, 2022
Enrollment StartJan 20, 2020
Primary CompletionDec 15, 2020
Study CompletionDec 30, 2024
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.3 years ago
Interventions
Esomeprazoledrug
Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
Placebodrug
Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan